XSHE
300255
Market cap3.01bUSD
Oct 09, Last price
22.15CNY
1D
1.19%
1Q
-15.91%
Jan 2017
180.38%
IPO
429.90%
Name
Hebei Changshan Biochemical Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
Key people
Jie Gao
Vice Chairman of the Board · since 2024
Xiaohua Yue
Chief Financial Officer, Deputy General Manager · since 2023
Wei Zhang
Chief Financial Officer, Secretary of the Board, Deputy General Manager · since 2011
Guohong An
Deputy General Manager · since 2021
Yanlu Chang
Deputy General Manager · since 2024
Zhongying Liu
Deputy General Manager, Secretary of the Board · since 2021
Xinjun Zhang
Deputy General Manager · since 2024
Qing Zhang
Deputy General Manager · since 2020
Tao Zhang
Deputy General Manager · since 2024
Xiaodong Gao
Chairman of the Board, General Manager · since 2024
Zhenggang Qie
Deputy General Manager, Director · since 2023
Yunxia Sun
Deputy General Manager, Director · since 2021
Deying Cao
Independent Director · since 2021
Xiangjun Wang
Independent Director · since 2021
Headquarters & legal address
中国(河北)自由贸易试验区正定片区正定县高新技术产业开发区南区梦龙街71号
石家庄市, HE 050000
CN
石家庄市, HE 050000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||